

Date: March 12, 2026

To
BSE Limited
25th Floor, PJ Towers
Dalal Street,
Mumbai-400001
Scrip Code: 524654

To
National Stock Exchange of India Limited
Exchange Plaza , C-1, Block G
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051
Symbol: NATCAPSUQ

Sub: Press Release

Dear Sir/Madam,

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copy of press release in connection with Natural Biogenex Private Limited (“Material Subsidiary”) has entered into “Framework & Contract Manufacturing agreements” with Fermbox Bio Private Limited.

We request you to kindly take the aforesaid information on record.

Thanking You

Yours Faithfully,

For Natural Capsules Limited

Pranjal Deshmukh
Company Secretary & Compliance Officer
M.No: A66119



Natural Biogenex and Fermbox Bio Enter Strategic Framework and Manufacturing Agreements to Strengthen Fermentation-Based CDMO Capabilities

Natural Biogenex Private Limited, a subsidiary of Natural Capsules Limited, has executed definitive Framework and Contract Manufacturing Agreements with Fermbox Bio Private Limited to jointly advance fermentation-based Contract Development and Manufacturing (CDMO) services. Under this collaboration, Fermbox will provide advanced fermentation technology and equipment placement of up to ₹60 crore at NBPL's state-of-the-art facility in Tumkur, while NBPL will undertake licensed manufacturing, quality assurance and regulatory compliance. The partnership positions the Company to serve global biotechnology and biopharma clients with integrated, GMP-compliant manufacturing capacity and enhanced process efficiency.

The global biotech and biopharma CDMO market continues to present strong growth opportunities, driven by rising demand, increasing outsourcing, and more complex biomanufacturing requirements. India is strategically placed to capture a meaningful share of this opportunity, tapping into its bio-manufacturing strength and a growing CDMO sector.

Key government catalysts like the BioE3 Policy and the RDI initiative are helping accelerate innovation and scale-up, while strengthening India's broader biomanufacturing ecosystem. This collaboration is aligned to benefit from that momentum

Comment from Managing Director, Mr. Sunil Laxminarayana Mundra:

"This partnership marks a pivotal step for Natural Biogenex and, by extension, for Natural Capsules Group, in expanding into high-value, fermentation-based bio-manufacturing CDMO service for pharma and allied products. The collaboration with Fermbox combines our licensed manufacturing strength and regulatory excellence with their advanced technology, enabling value-accretive, scalable growth in both pharmaceutical and industrial biotech segments."

ABOUT NATURAL CAPSULE LIMITED (NCL)

Natural Capsules Limited (NCL) is a hard capsule shell manufacturer, who pioneered manufacturing of vegetarian capsules in India and is the second largest Indian manufacturer for gelatin capsules. The company was incorporated as a Public Limited Company in 1993 at Bangalore, and it further expanded its operations to Pondicherry in 2003. The company is now foraying into API manufacturing with complex high-end patented technology developed in-house, under its subsidiary company Natural Biogenex Private Limited.

For further details please get in touch with

Pranjal Deshmukh

NATURAL CAPSULE LIMITED

Email: company.sec@naturalcapsules.com

Abhishek Mehra

TIL ADVISORS PRIVATE LIMITED

Email: abhishek@theinvestmentlab.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward- looking statements. Natural Capsules Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.